Stock listing
NASDAQ:BDSX Biodesix, Inc. Stock
Home listing (NASDAQ) of Biodesix, Inc.
Follow Biodesix, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BDSX
$7.56 USD -0.84 (-10.0%)
Close on Nov 20, 2026
- Day range
- $7.50 – $8.45 USDNov 20, 2026
- Volume
- 205,366 sharesNov 20, 2026
- Market cap
- $83.83M USDAt the close on Nov 20, 2026 · price × 11.09M shares outstanding
- 52-week range
- $5.26 – $31.97 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.08M USDMedian day 101,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BDSX · Home | $7.56 USD | -0.84 (-10.0%) | 205,366 | $8.17 | $8.445 | $7.50 | $8.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BDSX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.56 | -0.84 | -10.0% | $8.17 | $8.445 | $7.50 | 205,366 | |
| $8.40 | -0.48 | -5.4% | $8.75 | $9.04 | $8.36 | 168,629 | |
| $8.88 | -0.12 | -1.3% | $8.81 | $9.18 | $8.779 | 134,884 | |
| $9.00 | -0.88 | -8.9% | $9.86 | $9.86 | $8.885 | 258,896 | |
| $9.88 | +0.09 | +0.9% | $10.06 | $11.32 | $9.85 | 386,123 | |
| $9.79 | -0.33 | -3.3% | $10.17 | $10.85 | $9.70 | 297,068 | |
| $10.12 | +0.10 | +1.0% | $10.05 | $11.30 | $9.678 | 560,410 | |
| $10.02 | -0.32 | -3.1% | $10.20 | $10.60 | $9.39 | 575,482 | |
| $10.34 | +1.81 | +21.2% | $8.318 | $10.94 | $7.72 | 907,423 | |
| $8.53 | -11.31 | -57.0% | $12.42 | $13.04 | $7.96 | 1,586,800 | |
| $19.84 | -1.65 | -7.7% | $21.30 | $21.30 | $19.07 | 185,600 | |
| $21.49 | +0.44 | +2.1% | $21.56 | $22.23 | $20.42 | 148,000 | |
| $21.05 | -0.73 | -3.4% | $21.80 | $22.89 | $20.74 | 38,800 | |
| $21.78 | -1.475 | -6.3% | $23.24 | $23.31 | $21.37 | 75,600 | |
| $23.26 | -1.465 | -5.9% | $25.06 | $25.06 | $22.70 | 67,100 | |
| $24.72 | +1.86 | +8.1% | $22.94 | $24.87 | $22.94 | 70,100 | |
| $22.86 | +0.91 | +4.1% | $21.87 | $22.98 | $21.27 | 101,300 | |
| $21.95 | +0.69 | +3.2% | $21.41 | $22.43 | $20.11 | 141,700 | |
| $21.26 | +0.08 | +0.4% | $21.54 | $22.36 | $21.02 | 60,900 | |
| $21.18 | -2.76 | -11.5% | $23.66 | $23.70 | $21.11 | 139,600 | |
| $23.94 | +0.01 | 0.0% | $23.76 | $24.99 | $23.38 | 138,800 | |
| $23.93 | +0.06 | +0.3% | $24.07 | $24.55 | $23.66 | 54,200 | |
| $23.87 | +0.47 | +2.0% | $23.50 | $24.92 | $23.50 | 49,300 | |
| $23.40 | -0.26 | -1.1% | $23.68 | $25.24 | $23.04 | 55,400 | |
| $23.66 | -1.05 | -4.2% | $24.79 | $24.79 | $22.60 | 79,600 | |
| $24.71 | +0.72 | +3.0% | $23.92 | $24.77 | $23.84 | 35,200 | |
| $23.99 | -1.01 | -4.0% | $24.92 | $25.08 | $23.65 | 80,900 | |
| $25.00 | -0.70 | -2.7% | $25.79 | $25.79 | $24.80 | 53,300 | |
| $25.70 | -0.32 | -1.2% | $26.02 | $26.62 | $25.19 | 41,000 | |
| $26.02 | +0.39 | +1.5% | $25.68 | $26.64 | $25.63 | 46,700 | |
| $25.63 | -0.79 | -3.0% | $26.24 | $26.51 | $25.10 | 96,000 | |
| $26.42 | -1.54 | -5.5% | $27.50 | $27.78 | $26.07 | 57,600 | |
| $27.96 | -1.10 | -3.8% | $29.30 | $29.99 | $27.52 | 102,200 | |
| $29.06 | +1.34 | +4.8% | $27.72 | $30.00 | $26.53 | 181,200 | |
| $27.72 | +0.39 | +1.4% | $27.55 | $28.72 | $26.97 | 124,300 | |
| $27.33 | -2.50 | -8.4% | $29.45 | $29.70 | $26.33 | 178,900 | |
| $29.83 | +0.69 | +2.4% | $29.15 | $30.13 | $28.14 | 161,300 | |
| $29.14 | -1.28 | -4.2% | $30.57 | $31.21 | $28.56 | 142,600 | |
| $30.42 | +1.32 | +4.5% | $29.00 | $31.97 | $28.50 | 204,700 | |
| $29.10 | -0.30 | -1.0% | $29.47 | $30.17 | $28.48 | 98,300 | |
| $29.40 | +0.11 | +0.4% | $29.22 | $31.35 | $28.81 | 120,500 | |
| $29.29 | +1.14 | +4.0% | $27.99 | $29.49 | $27.65 | 69,000 | |
| $28.15 | -0.28 | -1.0% | $28.37 | $29.07 | $27.75 | 57,000 | |
| $28.43 | -0.77 | -2.6% | $29.36 | $29.99 | $27.56 | 122,400 | |
| $29.20 | +0.39 | +1.4% | $28.52 | $29.96 | $28.39 | 100,900 | |
| $28.81 | +0.25 | +0.9% | $28.99 | $29.42 | $28.52 | 60,800 | |
| $28.56 | +0.86 | +3.1% | $27.77 | $29.00 | $27.55 | 100,500 | |
| $27.70 | +0.30 | +1.1% | $27.40 | $28.00 | $26.42 | 69,400 | |
| $27.40 | +0.435 | +1.6% | $26.80 | $27.70 | $25.75 | 55,000 | |
| $26.97 | +0.925 | +3.6% | $26.12 | $27.14 | $25.82 | 46,400 | |
| $26.04 | -1.04 | -3.8% | $26.83 | $27.37 | $25.60 | 53,500 | |
| $27.08 | +0.45 | +1.7% | $26.77 | $27.80 | $26.70 | 33,400 | |
| $26.63 | +0.45 | +1.7% | $25.97 | $27.90 | $25.89 | 86,400 | |
| $26.18 | -0.295 | -1.1% | $26.23 | $26.76 | $25.42 | 58,800 | |
| $26.48 | -0.685 | -2.5% | $27.29 | $27.29 | $25.95 | 56,500 | |
| $27.16 | +2.09 | +8.3% | $25.21 | $27.40 | $24.07 | 141,200 | |
| $25.07 | -1.275 | -4.8% | $25.83 | $26.53 | $25.02 | 67,500 | |
| $26.35 | -0.485 | -1.8% | $26.71 | $27.10 | $25.76 | 58,000 | |
| $26.83 | -1.65 | -5.8% | $28.29 | $28.62 | $26.65 | 108,500 | |
| $28.48 | -2.12 | -6.9% | $30.64 | $31.06 | $28.32 | 162,300 | |
| $30.60 | +2.525 | +9.0% | $28.34 | $31.31 | $28.00 | 216,000 | |
| $28.08 | +2.685 | +10.6% | $25.70 | $30.00 | $25.41 | 198,000 | |
| $25.39 | -1.24 | -4.7% | $26.25 | $26.83 | $23.95 | 244,000 | |
| $26.63 | +2.60 | +10.8% | $24.25 | $27.11 | $24.11 | 272,600 | |
| $24.03 | -1.51 | -5.9% | $25.20 | $26.00 | $23.76 | 229,200 |
Splits
1 split · NASDAQ:BDSX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:BDSX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
Latest earnings call · Nov 5, 2026
Biodesix (NASDAQ:BDSX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 29 slides
Latest news
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
Nov 9, 2026
Closed $10.34 (+21.2%) on Nov 9, 2026
Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)
Nov 5, 2026
Closed $8.53 (-57.0%) on Nov 6, 2026
Biodesix Announces Third Quarter 2026 Results and Highlights
Nov 5, 2026
Closed $8.53 (-57.0%) on Nov 6, 2026
Biodesix to Participate in Upcoming Investor Conferences
Nov 4, 2026
Closed $21.49 (+2.1%) on Nov 4, 2026
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
Oct 22, 2026
Closed $23.94 (0.0%) on Oct 22, 2026
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
Oct 19, 2026
Closed $23.87 (+2.0%) on Oct 20, 2026
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Oct 19, 2026
Closed $23.40 (-1.1%) on Oct 19, 2026
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
Oct 13, 2026
Closed $25.00 (-2.7%) on Oct 13, 2026
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Sep 14, 2026
Closed $27.70 (+1.1%) on Sep 15, 2026
Biodesix Announces Second Quarter 2026 Results and Highlights
Aug 5, 2026
Closed $22.10 (-3.0%) on Aug 6, 2026
Biodesix, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 22 in the last 12 months · 130 in all · newest Nov 9, 2026 · oldest 2020
- Calls
- 24 calls with a replay · 24 with a transcript · latest Nov 5, 2026
- Decks
- 6 decks · latest November 2026
Where Biodesix, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BDSX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BDSX | BOATS | United States | USD |
Valuation
EV/sales 1.0× against a median of 2.6×: 4th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $105.4M USD
- P/E
- Loss
- EV/sales
- 1.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 9.7×
- Gross margin
- Not reported
- Operating margin
- −18.7%
- Net margin
- −25.7%
- Debt to equity
- 5.8×
- Beta vs S&P 500
- 1.56
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Biodesix, Inc. · NASDAQ:BDSX | US$83.83M | US$105.4M | n/a | 1.0× | n/a | 9.7× | −25.7% | 5.8× | 1.56 |
| BICO Group AB Class B · OMXSTO:BICO | US$102.7M | US$90.50M | n/a | 0.6× | 2.1× | 0.8× | −28.3% | 0.3× | n/a |
| Devyser Diagnostics AB · OMXSTO:DVYSR | US$99.24M | US$94.86M | 39.9× | 3.8× | 17.5× | 2.6× | 10.0% | 0.1× | n/a |
| Quanterix Corporation · NASDAQ:QTRX | US$93.06M | US$47.06M | n/a | 0.3× | n/a | 0.4× | −75.0% | 0.1× | 1.87 |
| Exagen Inc. · NASDAQ:XGN | US$92.10M | US$86.82M | n/a | 1.2× | n/a | 6.7× | −25.1% | 1.7× | 2.52 |
| Bonraybio Co. Ltd. · TWSE:6955 | US$81.85M | US$65.60M | 25.0× | 6.5× | 18.1× | 4.1× | 32.5% | 0.0× | n/a |
| Nightingale Health Oyj Class B · OMXHEX:HEALTH | US$77.17M | US$36.79M | n/a | 6.1× | n/a | 1.4× | −335.7% | 0.0× | n/a |
| Lucid Diagnostics Inc. · NASDAQ:LUCD | US$77.14M | US$77.63M | n/a | 14.3× | n/a | 13.0× | −892.8% | 3.1× | 1.36 |
| Seer, Inc. · NASDAQ:SEER | US$75.91M | −US$58.25M | n/a | −4.1× | n/a | 0.4× | −450.9% | 0.1× | 1.03 |
| Selvita SA · GPW:SLV | US$75.22M | US$113.4M | n/a | 1.4× | 9.1× | 1.0× | −0.6% | 0.5× | n/a |
| Sera Prognostics, Inc. · NASDAQ:SERA | US$69.65M | US$28.84M | n/a | 300× | n/a | 1.3× | n/a | 0.1× | 0.57 |
| Median of the others | US$79.51M | US$71.62M | 32.5× | 2.6× | 13.3× | 1.4× | −28.3% | 0.1× | 1.36 |
Forecasts
7 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 32.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.90 · 7 analysts
- Revenue, year to Dec 2026
- 104.7M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Scott Hutton | Chief Executive Officer |
| Robin Harper Cowie | Chief Financial Officer |
| Brianna Phillips | Vice President, Quality and Regulatory Affairs |
| Jessica Olbricht | Vice President, Human Resources |
| Niki Givens | Vice President, Clinical Research |
| Gary Pestano | Chief Scientific Officer |
| James R. Jett | Co-Chief Medical Officer |
| Steve Springmeyer | Co-Chief Medical Officer |
Board
| Director | Role |
|---|---|
| John Patience | Chairman of the Board |
| Hany Massarany | Director |
| Jean M. Franchi | Director |
| Jon Faiz Kayyem | Director |
| Lawrence T. Kennedy | Director |
| Matthew W. Strobeck | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Biodesix (NASDAQ:BDSX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q1 2026 Earnings Call | Mon, May 04, 2026 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q1 2025 Earnings Call | Tue, May 13, 2025 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q4 2024 Earnings Call | Thu, Apr 03, 2025 · 4:30 PM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q3 2024 Earnings Call | Fri, Nov 01, 2024 · 8:30 AM ET | Replay |
| Biodesix (NASDAQ:BDSX) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 4:30 PM ET | Replay |
All 24 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −57.0% |
| Q2 2026 | Aug 5, 2026 · After close | −3.0% |
| Q1 2026 | May 4, 2026 · After close | +32.6% |
| Q4 2025 | Feb 26, 2026 | +18.6% |
| Q3 2025 | Nov 3, 2025 · After close | +19.9% |
| Q2 2025 | Aug 7, 2025 · After close | −10.4% |
| Q1 2025 | May 13, 2025 · After close | −38.7% |
| Q4 2024 | Feb 27, 2025 · Before open | −2.2% |
| Q3 2024 | Nov 1, 2024 · Before open | −23.5% |
| Q2 2024 | Aug 7, 2024 · After close | +3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | 0.0% |
| Q4 2023 | Mar 1, 2024 · Before open | +2.6% |
| Q3 2023 | Nov 7, 2023 · After close | −10.1% |
| Q2 2023 | Aug 7, 2023 · After close | +3.9% |
| Q1 2023 | May 11, 2023 · After close | −12.3% |
| Q4 2022 | Mar 6, 2023 · Before open | −10.0% |
| Q3 2022 | Nov 3, 2022 · Before open | +2.8% |
| Q2 2022 | Aug 4, 2022 · Before open | +4.7% |
| Q1 2022 | May 11, 2022 · Before open | −15.4% |
| Q4 2021 | Feb 14, 2022 · Before open | −0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 29 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 34 slides | August 2026 |
| Q2 2025 Earnings Presentation | Earnings | 32 slides | Aug 7, 2025 |
| Investor Presentation (August 2024) | Investor deck | 24 slides | Aug 15, 2024 |
| Investor Presentation (September 2021) | Investor deck | 22 slides | Sep 9, 2021 |
| Investor Presentation (January 2021) | Investor deck | 50 slides | Jan 8, 2021 |
IPO
Priced at US$18.00 a share on Oct 27, 2020.
- Price
- US$18.00 a share
- Shares offered
- 4,000,000 shares of common stock
- Offering size
- US$72 million
- Underwriters' option
- Up to 600,000 more shares
- Underwriters
- MORGAN STANLEY, WILLIAM BLAIR, CANACCORD GENUITY, BTIG · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 12, 2020 |
| Filed publicly | Oct 2, 2020 |
| Amended 4 times | Newest Oct 26, 2020 |
| Shares registered with an exchange | Oct 26, 2020 |
| Declared effective by the SEC | Oct 27, 2020 |
| Final prospectus, with the price | Oct 29, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 29, 2020 |
| EFFECT · Notice that a registration is effective | Oct 27, 2020 |
| CERT · Exchange's certificate of listing | Oct 26, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 26, 2020 |
| S-1/A · Registration statement, amended | Oct 26, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| S-1/A · Registration statement, amended | Oct 21, 2020 |
| CORRESP · Letter to the SEC | Oct 19, 2020 |
All 21 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Oct 19, 2020 |
| CORRESP · Letter to the SEC | Oct 16, 2020 |
| S-1/A · Registration statement, amended | Oct 14, 2020 |
| CORRESP · Letter to the SEC | Oct 13, 2020 |
| UPLOAD · Letter from the SEC | Oct 9, 2020 |
| S-1/A · Registration statement, amended | Oct 9, 2020 |
| S-1 · Registration statement | Oct 2, 2020 |
| DRS/A · Draft registration statement, amended | Sep 22, 2020 |
| DRSLTR · Letter to the SEC with a draft | Sep 21, 2020 |
| UPLOAD · Letter from the SEC | Sep 10, 2020 |
| DRS · Draft registration statement | Aug 12, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 29, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 88.5M | 71.3M | 49.1M | 38.2M | 54.5M | 45.6M | 24.6M | 20.4M |
| Cost of revenue | 16.7M | 15.6M | 13.0M | 14.2M | 30.5M | 22.0M | 6.07M | 4.41M |
| Gross profit | 71.8M | 55.8M | 36.1M | 24.1M | 24.0M | 23.6M | 18.5M | 16.0M |
| Research and development | 12.0M | 9.56M | 9.99M | 13.1M | 12.8M | 10.8M | 10.5M | 8.19M |
| Selling, general and administrative | 87.5M | 80.5M | 67.4M | 61.5M | 50.5M | 34.9M | 30.6M | 25.9M |
| Operating income | -27.9M | -34.5M | -41.3M | -50.6M | -40.9M | -22.9M | -26.7M | -23.5M |
| Depreciation and amortization | 5.67M | 5.77M | 3.33M | 3.60M | 3.18M | 2.90M | 2.79M | 1.74M |
| EBITDA | -22.2M | -28.7M | -38.0M | -47.0M | -37.8M | -20.0M | -23.9M | -21.7M |
| Interest expense | 7.72M | 8.26M | 9.54M | 8.07M | 4.51M | 7.60M | 3.01M | 2.92M |
| Income before tax | -35.3M | -42.9M | -52.1M | -65.4M | -43.2M | -31.4M | -30.7M | -26.2M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 629.0K | 211.0K |
| Net income | -35.3M | -42.9M | -52.1M | -65.4M | -43.2M | -65.4M | -30.7M | -26.2M |
| Earnings per share, basic | -4.67 | -6.64 | -0.64 | -1.55 | -1.58 | -6.48 | -126.97 | -19.72 |
| Earnings per share, diluted | -4.67 | -6.64 | -0.64 | -1.55 | -1.58 | -6.48 | -126.97 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 19.0M | 26.2M | 26.3M | 43.1M | 32.7M | 62.1M | 5.29M | 5.91M |
| Receivables | 9.04M | 8.60M | 7.68M | 5.07M | 3.66M | 15.3M | 5.29M | 1.89M |
| Inventory | 1.40M | 1.40M | 2.90M | 3.20M | 800.0K | 700.0K | ||
| Current assets | 32.5M | 39.5M | 39.7M | 53.3M | 43.6M | 86.1M | 12.7M | 9.91M |
| Property, plant and equipment | 24.8M | 27.8M | 27.9M | 5.85M | 4.18M | 3.18M | 2.12M | 1.39M |
| Goodwill | 15.0M | 15.0M | 15.0M | 15.0M | 15.0M | 15.0M | 15.0M | 10.8M |
| Total assets | 87.5M | 97.2M | 99.1M | 92.9M | 76.1M | 121.1M | 45.0M | 39.1M |
| Accounts payable | 3.08M | 2.19M | 2.93M | 1.69M | 1.66M | 8.96M | 1.72M | 886.0K |
| Current liabilities | 17.4M | 14.3M | 33.4M | 22.8M | 29.0M | 32.1M | 22.6M | 4.47M |
| Long-term debt | 47.4M | 36.4M | 35.2M | 25.0M | 9.99M | 15.9M | 23.8M | 23.1M |
| Total debt | 50.0M | 40.0M | 40.1M | 30.1M | 10.1M | 28.1M | 36.0M | 23.1M |
| Total liabilities | 89.9M | 76.4M | 94.5M | 72.3M | 56.4M | 79.9M | 76.2M | 237.1M |
| Shareholders' equity | -2.46M | 20.9M | 4.58M | 20.6M | 19.7M | 41.2M | -225.1M | -198.0M |
| Shares outstanding | 8.25M | 7.27M | 96.2M | 77.6M | 30.8M | 26.6M | 254.9K | 1.33M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.3M | -48.6M | -22.9M | -45.0M | -28.2M | -21.4M | -21.7M | -17.7M |
| Capital spending | -259.0K | -3.23M | -22.9M | -3.30M | -2.24M | -1.95M | -1.31M | -617.0K |
| Free cash flow | -23.5M | -51.9M | -45.8M | -48.3M | -30.5M | -23.3M | -23.0M | -18.3M |
| Cash from investing | -403.0K | -3.44M | -23.1M | -3.53M | -2.55M | -2.93M | -1.87M | -617.0K |
| Cash from financing | 16.4M | 52.0M | 29.1M | 58.9M | 1.26M | 81.1M | 23.0M | 19.0M |
| Dividends paid | -643.0K | -328.0K | ||||||
| Share buybacks | 497.0K | 625.0K | 643.0K | 355.0K | 328.0K | |||
| Change in cash | -7.26M | -39.0K | -16.8M | 10.4M | -29.5M | 56.8M | -626.0K | 738.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 5, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 18, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 1, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 29, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 26, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 21, 2026 | Offer document | SEC |
| 8-K · Current report | May 20, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 9, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 13, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 8-K · Current report | May 21, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 20, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 28, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 7, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 10, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 13, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 13, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 12, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Nov 12, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 7, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Nov 6, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 6, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 1, 2024 | Offer document | SEC |
| S-3 · Registration statement | Nov 1, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 1, 2024 | Results | SEC |
| 8-K · Current report | Aug 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Aug 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 18, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 24, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 5, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 31, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 24, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 24, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 23, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | May 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 23, 2024 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | May 17, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | May 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 10, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 9, 2024 | Other filings | SEC |
This page holds 200 of 602 filings. Open Filings
Cap table
Built by 6ix from Biodesix, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 11,088,511
- Fully diluted
- 11,088,511
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 11,088,511 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 11,088,511 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jack W Schuler Other companies: Hansen Medical Inc (Director · Aug 8, 2013 – Jun 15, 2015 · Past); Accelerate Diagnostics Inc (Director · Jun 26, 2012 – Dec 3, 2024 · Past); Oncternal Therapeutics Inc (Director · Mar 1, 2012 – Mar 1, 2012 · Past); Icos Corp (Director · May 11, 2006 – Jan 29, 2007 · Past); Stericycle Inc (Director · May 3, 2006 – Apr 30, 2018 · Past); Medtronic plc. (Director · Jan 27, 2006 – Jun 27, 2013 · Past) | Director · Since at least Jun 22, 2020 |
| Jean Franchi Other companies: Disc Medicine, Inc. (Chief Financial Officer · Since at least Feb 7, 2024); Replimune Group, Inc. (Chief Financial Officer · Dec 9, 2019 – May 16, 2023 · Past); Merrimack Pharmaceuticals Inc (Chief Financial Officer · Feb 15, 2018 – Dec 11, 2018 · Past) | Director · Since at least Oct 27, 2020 |
| Jon Faiz Kayyem Other companies: Inhibrx Biosciences, Inc. (Director · Since at least May 24, 2024); Inhibrx Inc (Director · Aug 18, 2020 – May 30, 2024 · Past); GenMark Diagnostics Inc (SVP, Research & Development · May 28, 2010 – Feb 2, 2018 · Past) | Director · Since at least Dec 6, 2021 |
| Ryan Siurek Other companies: EverCommerce Inc. (Chief Financial Officer · Since at least Jul 10, 2023); Vail Resorts, Inc. (SVP, Controller & CAO · Apr 18, 2016 – Sep 28, 2020 · Past); SPRINT Corp (Vice President and Controller · Nov 6, 2009 – Jul 24, 2013 · Past) | Chief Accounting Officer · Dec 31, 2020 – May 8, 2023 · Past |
| Hany Massarany Other companies: Accelerate Diagnostics Inc (Director · May 20, 2021 – Jun 28, 2024 · Past); GenMark Diagnostics Inc (President and CEO, Director · Nov 2, 2017 – Jan 23, 2020 · Past) | Director · Since at least Jul 1, 2020 |
| John Patience Other companies: Accelerate Diagnostics Inc (Director · Jun 26, 2012 – Dec 3, 2024 · Past); Stericycle Inc (Director · May 3, 2006 – May 23, 2018 · Past) | Chairman of the Board · Since at least Jun 23, 2020 |
| Matthew W. Strobeck Other companies: QuidelOrtho Corporation (Director · Since at least May 27, 2022); Accelerate Diagnostics Inc (Director · Apr 1, 2019 – Jan 23, 2024 · Past) | Director · Since at least Jun 18, 2020 |
| Charles M Watts Other companies: Accelerate Diagnostics Inc (Director · Apr 1, 2019 – May 19, 2023 · Past) | Director · Oct 27, 2020 – Mar 31, 2025 · Past |
| Scott Hutton Other companies: The Spectranetics Corp (General Manager, VI · Jan 23, 2017 – Aug 9, 2017 · Past) | Chief Executive Officer · Since at least Oct 27, 2020 |
| Brianna Phillips | Vice President, Quality and Regulatory Affairs · Since at least Sep 14, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Chris Vazquez | Chief Accounting Officer · Since at least Jul 3, 2023 |
| Gary Pestano | Chief Development Officer · Since at least Oct 27, 2020 |
| James Jett | Co-Chief Medical Officer · Since at least Mar 20, 2026 |
| Jessica Olbricht | Vice President, Human Resources · Since at least Nov 5, 2026 |
| Kieran O'Kane | Chief Commercial Officer · Since at least Oct 27, 2020 |
| Lawrence T. Kennedy | Director · Since at least Nov 5, 2026 |
| Lawrence T Kennedy Jr | Director · Since at least Jan 3, 2023 |
| Niki Givens | Vice President, Clinical Research · Since at least Nov 5, 2026 |
| Robert William Georgantas III | Chief Scientific Officer · Oct 27, 2020 – Nov 21, 2022 · Past |
| Robin Harper Cowie | CFO, Sec'y & Treasurer · Since at least Oct 27, 2020 |
| Steve Springmeyer | Co-Chief Medical Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Biodesix, Inc.